Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ligand Pharmaceuticals's price to sales ratio was 21.7× on Nov 11, 2026, against 15.9× a year earlier. Over the last 5 years it ranged from 5.0× to 23.1×, with a median of 12.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.7× | +6.9 |
| 2025 | Dec 31, 2025 | 14.8× | +1.6 |
| 2024 | Dec 31, 2024 | 13.2× | +5.1 |
| 2023 | Dec 29, 2023 | 8.1× | +2.5 |
| 2022 | Dec 30, 2022 | 5.6× | −4.5 |
| 2021 | Dec 31, 2021 | 10.1× | −1.0 |
| 2020 | Dec 31, 2020 | 11.2× | +11.1 |
| 2019 | Dec 31, 2019 | 0.0× | −11.4 |
| 2018 | Dec 31, 2018 | 11.4× | −1.2 |
| 2017 | Dec 29, 2017 | 12.6× | −10.5 |
| 2016 | Dec 30, 2016 | 23.1× | −6.2 |
| 2015 | Dec 31, 2015 | 29.3× | +10.3 |
| 2014 | Dec 31, 2014 | 19.0× | −4.6 |
| 2013 | Dec 31, 2013 | 23.7× | +9.9 |
| 2012 | Dec 31, 2012 | 13.8× | +2.7 |
| 2011 | Dec 30, 2011 | 11.1× | +6.8 |
| 2010 | Dec 31, 2010 | 4.3× | – |
See a number that looks wrong?